Haemonetics SEC Filings

Type
Bericht
Datum
10-QQuartalsbericht5-2-2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5-2-2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben9-1-2026
4Insidertransaktion12-11-2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6-11-2025
10-QQuartalsbericht6-11-2025
4Insidertransaktion3-11-2025
4Insidertransaktion24-9-2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular12-8-2025
10-QQuartalsbericht7-8-2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben7-8-2025
4Insidertransaktion25-7-2025
4Insidertransaktion25-7-2025
4Insidertransaktion25-7-2025
4Insidertransaktion25-7-2025
4Insidertransaktion25-7-2025
4Insidertransaktion25-7-2025
4Insidertransaktion25-7-2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben25-7-2025
4Insidertransaktion25-7-2025
144144-Formular26-6-2025
4/A4/A-Formular13-6-2025
4/A4/A-Formular13-6-2025
144144-Formular12-6-2025
4Insidertransaktion9-6-2025
4Insidertransaktion9-6-2025
DEF 14ADEF 14A-Formular6-6-2025
ARSARS-Formular6-6-2025
DEFA14ADEFA14A-Formular6-6-2025
144144-Formular4-6-2025
4Insidertransaktion3-6-2025
4Insidertransaktion3-6-2025
4Insidertransaktion3-6-2025
4Insidertransaktion3-6-2025
144144-Formular2-6-2025
SDSD-Formular27-5-2025
10-KJahresbericht21-5-2025
4Insidertransaktion20-5-2025
4Insidertransaktion20-5-2025
4Insidertransaktion20-5-2025
4Insidertransaktion20-5-2025
4Insidertransaktion20-5-2025
4Insidertransaktion20-5-2025
4Insidertransaktion20-5-2025
4Insidertransaktion19-5-2025
4Insidertransaktion19-5-2025
4Insidertransaktion19-5-2025
4Insidertransaktion19-5-2025
144144-Formular19-5-2025
4Insidertransaktion19-5-2025
4Insidertransaktion19-5-2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular14-5-2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular12-5-2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8-5-2025
4Insidertransaktion5-5-2025
33-Formular9-4-2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular4-4-2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3-3-2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6-2-2025
10-QQuartalsbericht6-2-2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben14-1-2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3-1-2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3-12-2024
SC 13GSC 13G-Formular14-11-2024
SC 13G/ABeneficial ownership report12-11-2024
144144-Formular12-11-2024
SC 13G/ABeneficial ownership report8-11-2024
10-QQuartalsbericht7-11-2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben7-11-2024
4Insidertransaktion5-11-2024
4Insidertransaktion18-9-2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben16-9-2024
4Insidertransaktion3-9-2024
10-QQuartalsbericht8-8-2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8-8-2024
8-K/A8-K/A-Formular30-7-2024
4Insidertransaktion29-7-2024
4Insidertransaktion26-7-2024
4Insidertransaktion26-7-2024
4Insidertransaktion26-7-2024
4Insidertransaktion26-7-2024
4Insidertransaktion26-7-2024
4Insidertransaktion26-7-2024
4Insidertransaktion26-7-2024
4Insidertransaktion26-7-2024
144144-Formular26-7-2024
4Insidertransaktion26-7-2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben25-7-2024
4Insidertransaktion15-7-2024
144144-Formular12-7-2024
144144-Formular11-7-2024
4Insidertransaktion7-6-2024
ARSARS-Formular7-6-2024
DEF 14ADEF 14A-Formular7-6-2024
DEFA14ADEFA14A-Formular7-6-2024
4Insidertransaktion29-5-2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben29-5-2024
144144-Formular29-5-2024
4Insidertransaktion29-5-2024
4Insidertransaktion29-5-2024

Haemonetics Documenten 2026

Deze pagina bevat alle officiële documenten en SEC-filings voor Haemonetics aandelen (HAE, ISIN: US4050241003). Dit omvat jaarverslagen (Formulier 10-K), kwartaalrapporten (Formulier 10-Q) en insidertransacties (Formulier 4). Momenteel zijn 100 documenten beschikbaar. Gegevens worden regelmatig bijgewerkt om beleggers een volledig overzicht van Haemonetics's regelgevingsfilings te bieden.

Haemonetics Aandelenanalyse

Haemonetics Haemonetics Corp is a leading provider of blood processing and transfusion products. The company was founded in 1971 by Dr. Jack Latham to create a better solution for the storage and transfer of blood products. Since then, the company has become a major provider of products and services for the blood transfusion industry. Haemonetics' business model is focused on the development, manufacturing, and marketing of products and devices for blood transfusion. The company offers a wide range of products and services, including blood processing systems, blood collection and maintenance devices, software solutions, blood components, and related accessories. In recent years, Haemonetics has dedicated itself to diversifying its offerings. While still focusing on the blood transfusion industry, the company has also expanded into other areas, such as the treatment of patients with blood disorders and the development of devices for cell therapy. Haemonetics is divided into various business segments, including Blood Management Solutions, Diagnostic Solutions, and Haemonetics Software Solutions. The Blood Management Solutions segment includes a range of products, including blood collection and storage devices, centrifuges, and hematocrit systems. Diagnostic Solutions provides diagnostic tests for blood disorders, including tests for coagulation disorders and thrombophilia. Haemonetics Software Solutions offers software solutions for the blood transfusion industry, including systems for automated processing and storage of blood products, as well as systems for automatic inventory management. Haemonetics' products also include devices for freezing blood products and for processing blood components. These devices help ensure that blood products are stored at optimal temperatures and conditions to ensure their effectiveness and usability for the patient. Another important area of Haemonetics' business is the development of devices for cell therapy. The company works closely with research institutes and biotech companies to develop innovative technologies for cell therapy. This includes the development of devices for the isolation and purification of stem cells that can be used for the treatment of cancer and other diseases. Haemonetics Corp has made a name for itself in the blood transfusion industry and continues to focus on innovation and diversification to fully utilize the potential of the company and its products. With a wide range of products and services, a strong commitment to research and development, and an unwavering focus on the needs of patients and healthcare providers, Haemonetics is well positioned to continue growing and expanding in the future.